Tibolone and Endometrial Cancer

@article{Vries2005TiboloneAE,
  title={Tibolone and Endometrial Cancer},
  author={C. Vries and S. Bromley and H. Thomas and R. Farmer},
  journal={Drug Safety},
  year={2005},
  volume={28},
  pages={241-249}
}
AbstractObjective: Case series and spontaneous reports of endometrial cancer have raised the question as to whether the use of tibolone (introduced into the UK in 1991) is associated with an increased risk of endometrial cancer. This study set out to evaluate whether tibolone use is associated with an increased risk of endometrial cancer. Methods: Age-adjusted incidence rate ratios (IRRs) of endometrial cancer were calculated for tibolone use compared with the use of other hormone replacement… Expand
Hormone replacement therapy and the risk of endometrial cancer: A systematic review.
TLDR
Use of unopposed estrogen, tibolone and sequential combined therapy increases the risk of endometrial cancer, while considering both regimen and type of progestin. Expand
Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women.
TLDR
Screeningendometrial histology shows a low prevalence of endometrial hyperplasia (0.18%) and no carcinoma, and is designed to provide evidence of the endometricrial safety of tibolone compared with estrogen and progestogen. Expand
Endometrial effects of tibolone.
TLDR
The Tibolone Histology of the Endometrium and Breast Endpoints Study results confirm previous findings that tibolone does not induce endometrial hyperplasia or carcinoma in postmenopausal women, and it is associated with a better vaginal bleeding profile than CEE/MPA. Expand
Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition.
TLDR
The finding of a strong increased risk of endometrial cancer with estrogen-only HT and a weaker association with combined HT supports the hypothesis that progestins have an attenuating effect on endometricrial cancer risk. Expand
Ovarian cancer and hormone replacement therapy in the Million Women Study
TLDR
Women who use HRT are at an increased risk of both incident and fatal ovarian cancer, and in women with epithelial tumours the relative risk for current versus never use of HRT was greater for serous than for mucinous, endometroid, or clear cell tumours. Expand
Menopausal hormone therapy and risk of endometrial cancer
TLDR
Risks were based on varying patterns of usage, with little information available regarding how endometrial cancer risk is affected by duration of use, type and/or dose of estrogen or progestin, or mode of administration. Expand
Colorectal Cancer Risk Reduction following Macrogol Exposure: A Cohort and Nested Case Control Study in the UK
TLDR
A reduced CRC risk associated with macrogol prescribing is observed after accounting for the lead time for CRC, and whether the association is causal and whether it can partly be explained by selective prescribing is required. Expand
Endometrial cancer after endometrial ablation vs medical management of abnormal uterine bleeding.
TLDR
No difference was observed in endometrial cancer rates, and there was no delay in diagnosis when comparingendometrial ablation vs medical management, according to Cox models. Expand
Tibolone: Selective Tissue Estrogen Activity Regulator Utilization in Postmenopausal Women
TLDR
Tibolone is a safe and effective therapy in early menopausal women and has the advantage over selective estrogen receptor modulators (SERMs) of increasing the vaginal maturation value. Expand
Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005
TLDR
Trends in the prescribing of hormone therapy in the UK appear to closely reflect new epidemiological evidence and prescribing advice, and a substantial and continuing increase in prescribing prevalence of bisphosphonates reinforces the need for research into the long-term risks and benefits of these therapies. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 23 REFERENCES
Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
TLDR
Postmenopausal women who use combined therapy of oestrogen with cyclic progestagen on a long-term basis have an increased risk of endometrial cancer compared with those who are not on hormone replacement, even when progestogen is added for 10 or more days per month. Expand
Hormone replacement therapy and endometrial cancer risk: a meta-analysis.
TLDR
Endometrial cancer risk increases substantially with long duration of unopposed estrogen use, and this increased risk persists for several years after discontinuation of estrogen therapy, similar to the increased risk of developing the disease. Expand
Risk of endometrial cancer following estrogen replacement with and without progestins.
TLDR
The risk of developing endometrial cancer is increased after long-term use of estrogens without progestins and with cyclically added progestin use, and Continuously added progESTins may be needed to minimize the endometricrial cancer risk associated with estrogen replacement therapy. Expand
Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
TLDR
Long-term tamoxifen users have a worse prognosis of endometrial cancers, which seems to be due to less favourable histology and higher stage, however, the benefit of tamoxIFen on breast-cancer survival far outweighs the increased mortality from endometricrial cancer. Expand
Exacerbation of adenomyosis in a postmenopausal woman taking tibolone associated with an elevation in serum CA 125
TLDR
A 50 year old woman (para 3) reached the menopause at 46 years of age and took hormone replacement therapy (HRT) in the form of Prempak-C, initially at a daily dose of 625 pg of conjugated oestrogens; this was later increased to 1.25 mg. Expand
Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy.
TLDR
Use of tibolone 2.5 mg daily for 1 year was associated with significantly less bleeding and spotting compared with daily continuous combined 2 mg estradiol and 1 mg norethisterone acetate in postmenopausal women in the presence of both minimal and nonprogressive increase of endometrial thickness associated with the two regimens. Expand
Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy.
TLDR
The first observation of induced endometrial regression without withdrawal bleeding is reported, for 176 postmenopausal women on HRT with progestogen addition 'on demand' medroxyprogesterone acetate, noresthisterone and tibolone were used to protect the endometrium. Expand
Org OD 14 and the endometrium.
Long-term therapy with (7 alpha,17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14; tibolone, Livial) has no influence on the endometrium in post-menopausal women. This wasExpand
Endometrial hyperplasia and adenocarcinoma during tibolone (Livial®) therapy
TLDR
The most likely explanation for high MSAFP following reduction is increased concentration of alpha-fetoprotein in the amniotic fluid due to tissue breakdown from the dead fetuses; MSA FP returns to the normal range 8 to 12 weeks after the reduction because by this time there is complete resorption of the dead Fetuses. Expand
Continuous combined hormone replacement therapy and risk of endometrial cancer.
TLDR
Women who had received continuous combined hormone replacement therapy for several years did not appear to be at any increased risk for endometrial cancer relative to women who had never received hormones replacement therapy and may in fact be at decreased risk for Endometrial Cancer. Expand
...
1
2
3
...